⌕
Arrowhead Pharmaceuticals · ARWR · Nasdaq
Tenet 33 · Weak
Compare
$42.99−2.76%At closeTenet 33 · Weak
$42.99−1.22 (−2.76%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Arrowhead Pharmaceuticals (ARWR) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is ARWR's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Business WireNov 17, 2026 · 16:30 ETCOMPANY'S OWN WORDS
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on October 22, 2026, the Compensation Committee of the…

ARWR −2.8% todayRead at source ↗
● Defense WorldNov 15, 2026 · 09:53 ETEARNINGS EXPECTED BY NOV 30
94,000 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR Bought by ACT Capital Partners L.P.

ACT Capital Partners L.P. acquired a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC…

ARWR −2.8% todayRead at source ↗
● Seeking AlphaNov 12, 2026 · 22:58 ETEARNINGS EXPECTED BY NOV 30
Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2026 Earnings Call Transcript

Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2026 Earnings Call Transcript…

ARWR −2.8% todayRead at source ↗
● MarketBeatNov 12, 2026 · 21:15 ETEARNINGS EXPECTED BY NOV 30
Arrowhead Pharmaceuticals Q4 Earnings Call Highlights

Arrowhead Pharmaceuticals NASDAQ: ARWR is preparing for a potential U.S. launch of its drug REDEMPLO in a larger patient population in the second quarter of 2027, as the company works to turn growing prescription demand …

ARWR −2.8% todayRead at source ↗
● Business WireNov 12, 2026 · 16:01 ETEARNINGS EXPECTED BY NOV 30
Arrowhead Pharmaceuticals Reports 2026 Fiscal Year-End Results

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2026 fiscal year ended September 30, 2026. The Company is hosting a conference call to…

ARWR −2.8% todayRead at source ↗
● Business WireNov 9, 2026 · 16:00 ET
Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events:2026 Jefferies Global Healthcare C…

ARWR −2.8% todayRead at source ↗
● Business WireNov 7, 2026 · 16:15 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY NOV 30
Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented results on two of the RNA interference (RNAi) based therapies in its cardiometabolic pipeline at the American Heart Associ…

ARWR −2.8% todayRead at source ↗
● Business WireNov 4, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed a refinancing with funds managed by Sixth Street that lowers its borrowing costs, improves near-term…

ARWR −2.8% todayRead at source ↗
● Business WireNov 2, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it will present important data at this week's American Heart Association Scientific Sessions in Chicago. AHA 2026 Ora…

ARWR −2.8% todayRead at source ↗
● Business WireOct 27, 2026 · 11:36 ET
Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce Triglycerides

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that adults in England and Wales who live with a rare metabolic condition called Familial Chylomicronaemia Syndrome (FCS) …

ARWR −2.8% todayRead at source ↗
● Defense WorldOct 17, 2026 · 03:29 ETEARNINGS EXPECTED BY NOV 30
Reviewing DBV Technologies (NASDAQ:DBVT) and Arrowhead Pharmaceuticals (NASDAQ:ARWR)

DBV Technologies (NASDAQ: DBVT - Get Free Report) and Arrowhead Pharmaceuticals (NASDAQ: ARWR - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based o…

ARWR −2.8% todayRead at source ↗
● Seeking AlphaOct 15, 2026 · 08:38 ETEARNINGS EXPECTED BY NOV 30
Arrowhead Pharmaceuticals: ARO-MAPT Results Unlock A New Platform

Arrowhead Pharmaceuticals, Inc. exceeded expectations with ARO-MAPT phase 1 results, achieving up to 85% CSF tau reduction and validating its subcutaneous CNS siRNA platform. ARWR plans to expand its CNS pipeline, initia…

ARWR −2.8% todayRead at source ↗
● Seeking AlphaOct 14, 2026 · 20:44 ETEARNINGS EXPECTED BY NOV 30
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses ARO-MAPT Interim Results and TRiM CNS Delivery Platform in Investigational CNS Pipeline Transcript

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses ARO-MAPT Interim Results and TRiM CNS Delivery Platform in Investigational CNS Pipeline Transcript…

ARWR −2.8% todayRead at source ↗
● MarketBeatOct 14, 2026 · 19:02 ETEARNINGS EXPECTED BY NOV 30
Arrowhead Pharmaceuticals Reports Up to 73% CSF Tau Reduction in Early ARO-MAPT Study

Arrowhead Pharmaceuticals NASDAQ: ARWR presented interim Phase I/II data for ARO-MAPT, an investigational small interfering RNA therapy designed to reduce tau protein expression in the central nervous system, alongside i…

ARWR −2.8% todayRead at source ↗
● Business WireOct 14, 2026 · 07:30 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY NOV 30
Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from an ongoing Phase 1/2a study of ARO-MAPT, the company's investigational RNA interference (RNAi) therap…

ARWR −2.8% todayRead at source ↗
● Business WireOct 7, 2026 · 07:30 ET
Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the United States Food and Drug Administration (FDA) has granted plozasiran entry in the Split Real Time Ap…

ARWR −2.8% todayRead at source ↗
● Defense WorldOct 6, 2026 · 03:21 ET
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Breaks Below 200 Day Moving Average – Here’s Why

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR - Get Free Report) shares crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $75.86 and traded as low as $62.22. Arr…

ARWR −2.8% todayRead at source ↗
● Seeking AlphaOct 2, 2026 · 22:20 ET
Arrowhead Pharmaceuticals: The Fast-Follower Math Behind A $215 Million Voucher

Arrowhead Pharmaceuticals is positioned to challenge Ionis in severe hypertriglyceridemia (sHTG) with plozasiran, leveraging a faster launch via a $215M priority review voucher. ARWR's SHASTA-3 and SHASTA-4 Phase III dat…

ARWR −2.8% todayRead at source ↗
● Business WireSep 29, 2026 · 07:30 ET
Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host an R&D webinar on Wednesday, October 14, 2026, at 11:30 AM PDT that will focus on investigation…

ARWR −2.8% todayRead at source ↗
● MarketBeatSep 18, 2026 · 20:02 ET
Arrowhead Pharmaceuticals Spotlights Dual-Target RNAi Data, Plozasiran Launch Progress

Arrowhead Pharmaceuticals NASDAQ: ARWR executives outlined early clinical data for its RNA interference dimer program, progress in the launch of plozasiran and plans for central nervous system and metabolic disease candi…

ARWR −2.8% todayRead at source ↗
● MarketBeatSep 18, 2026 · 17:03 ET
Arrowhead Pharmaceuticals Eyes SHTG Filing as RNAi Pipeline Expands

Arrowhead Pharmaceuticals NASDAQ: ARWR is expanding its commercial and clinical footprint around RNA interference therapies, with its recently launched triglyceride-lowering treatment REDEMPLO and several pipeline progra…

ARWR −2.8% todayRead at source ↗
● Seeking AlphaSep 16, 2026 · 12:01 ET
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript…

ARWR −2.8% todayRead at source ↗
● Seeking AlphaSep 15, 2026 · 14:11 ET
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

ARWR −2.8% todayRead at source ↗
● GuruFocusSep 15, 2026 · 08:00 ET
Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

[url="]Arrowhead Pharmaceuticals, Inc.[/url] (NASDAQ: ARWR) today announced interim topline data from a Phase 1/2a clinical trial of ARO-DIMER-PA, the company's…

ARWR −2.8% todayRead at source ↗

Expected by Nov 30. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

NVDA30−0.4%

Article counts from the last market-wide feed page, across every symbol we track and not just ARWR · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.